These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33771089)

  • 1. Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model.
    Hwang YJ; Hyeon SJ; Kim Y; Lim S; Lee MY; Kim J; Londhe AM; Gotina L; Kim Y; Pae AN; Cho YS; Seong J; Seo H; Kim YK; Choo H; Ryu H; Min SJ
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):856-868. PubMed ID: 33771089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.
    Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H
    Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.
    Park I; Hwang YJ; Kim T; Viswanath ANI; Londhe AM; Jung SY; Sim KM; Min SJ; Lee JE; Seong J; Kim YK; No KT; Ryu H; Pae AN
    J Comput Aided Mol Des; 2017 Oct; 31(10):877-889. PubMed ID: 28879500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
    Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ
    Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
    Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
    Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
    Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
    J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
    Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
    PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
    Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
    J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington's Disease.
    Gharaibeh A; Maiti P; Culver R; Heileman S; Srinageshwar B; Story D; Spelde K; Paladugu L; Munro N; Muhn N; Kolli N; Rossignol J; Dunbar GL
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations.
    Irmak D; Fatima A; Gutiérrez-Garcia R; Rinschen MM; Wagle P; Altmüller J; Arrigoni L; Hummel B; Klein C; Frese CK; Sawarkar R; Rada-Iglesias A; Vilchez D
    Hum Mol Genet; 2018 Dec; 27(23):4117-4134. PubMed ID: 30452683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
    Kim W; Seo H
    Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease.
    Lee J; Hwang YJ; Shin JY; Lee WC; Wie J; Kim KY; Lee MY; Hwang D; Ratan RR; Pae AN; Kowall NW; So I; Kim JI; Ryu H
    Acta Neuropathol; 2013 May; 125(5):727-39. PubMed ID: 23455440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.
    Chambon J; Komal P; Lewitus GM; Kemp GM; Valade S; Adaïdi H; Al Bistami N; Stellwagen D
    J Neurosci; 2023 Jan; 43(4):672-680. PubMed ID: 36517241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.